A person with SMA impacts the NHS on average £49,723 annually in direct costs, while a loss of productivity per unpaid caregiver costs the society £14,350 each year.
The first results of two surveys commissioned last year by Spinal Muscular Atrophy UK and supported by TreatSMA reveal that the costs resulting from SMA have been understimated to-date. SMA turns out a very expensive disease that costs the society millions of pounds each year.
Below is the first overview of the survey results as published by SMA UK. The results will feed into the debate to what extent treating SMA with Spinraza will be cost-effective for the NHS.